Verona Pharma plc Verona Pharma Appoints David Moskowitz Asvice President, Capital Markets Strategy & Investor Relations
January 07 2020 - 2:00AM
UK Regulatory
TIDMVRP
LONDON, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on respiratory diseases, announces the appointment of
David Moskowitz to the newly created position of Vice President, Capital
Markets Strategy & Investor Relations. Mr. Moskowitz will oversee the
Company's investor relations activities and will also work with the
senior leadership team to further develop Verona Pharma's public market
profile.
"We are delighted to welcome David to Verona Pharma," said Jan-Anders
Karlsson, PhD, CEO of Verona Pharma. "His experience and insights make
him ideally suited to support our investor relations programme and
goals. He will play an instrumental role in forming and implementing our
IR strategy as we plan to start Phase 3 trials with first-in-class
product candidate, ensifentrine, in 2020."
Most recently, Mr. Moskowitz performed strategic advisory and investor
relations work for emerging biopharmaceutical and molecular diagnostics
companies in his private consulting practice. Prior to this role, Mr.
Moskowitz served as Vice President, Investor Relations at both Trovagene
and Biocept, public molecular diagnostic companies focused on the liquid
biopsy testing market. He previously served as Director of Equity
Research at Caris & Co. and as Head of Healthcare Research at Friedman
Billings Ramsey. During his tenure in the financial services industry,
Mr. Moskowitz also held analyst positions at UBS Warburg and Roth
Capital Partners. In 2011, he received the StarMine Analyst Award as the
top stock picker among U.S. Biotechnology Analysts. He earned his BS in
Pharmacy from Rutgers University and his MBA in Finance and
Pharmaceutical Industry Studies from Fairleigh Dickinson University.
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, ensifentrine, has the potential to be the
first therapy for the treatment of respiratory diseases that combines
bronchodilator and anti-inflammatory activities in one compound. Verona
Pharma is currently in Phase 2 development with three formulations of
ensifentrine for the treatment of COPD: nebulized, dry powder inhaler,
and pressurized metered-dose inhaler. Ensifentrine also has potential
applications in cystic fibrosis, asthma and other respiratory diseases.
For more information, please visit
https://www.globenewswire.com/Tracker?data=NzXx0LYieS-9P1LNXNw9e3LSOrEpz0MNRESGCF993Jq_oBeCSwM6Nfwj-XJ20NRi6HWrPivQlWqqNLE4rDItS5eMm7gRLEiWFfFtDAIeKis=
www.veronapharma.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, but not limited to, the development of ensifentrine, the
progress and timing of clinical trials and data, estimates of medical
costs for COPD, ensifentrine as a first-in-class phosphodiesterase 3 and
4 inhibitor, and plans to develop ensifentrine for the treatment of
cystic fibrosis and asthma.
These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from our expectations expressed or implied by
the forward-looking statements, including, but not limited to, the
following: our limited operating history; our need for additional
funding to complete development and commercialization of ensifentrine,
which may not be available and which may force us to delay, reduce or
eliminate our development or commercialization efforts; the reliance of
our business on the success of ensifentrine, our only product candidate
under development; economic, political, regulatory and other risks
involved with international operations; the lengthy and expensive
process of clinical drug development, which has an uncertain outcome;
serious adverse, undesirable or unacceptable side effects associated
with ensifentrine, which could adversely affect our ability to develop
or commercialize ensifentrine; potential delays in enrolling patients,
which could adversely affect our research and development efforts and
the completion of our Phase 2b trial; we may not be successful in
developing ensifentrine for multiple indications; our ability to obtain
approval for and commercialize ensifentrine in multiple major
pharmaceutical markets; misconduct or other improper activities by our
employees, consultants, principal investigators, and third-party service
providers; material differences between our "top-line" data and final
data; our reliance on third parties, including clinical investigators,
manufacturers and suppliers, and the risks related to these parties'
ability to successfully develop and commercialize ensifentrine; and
lawsuits related to patents covering ensifentrine and the potential for
our patents to be found invalid or unenforceable. These and other
important factors under the caption "Risk Factors" in our Annual Report
on Form 20-F filed with the Securities and Exchange Commission ("SEC")
on March 19, 2019, and our other reports filed with the SEC, could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of the
date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim any
obligation to do so, even if subsequent events cause our views to
change. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this
press release.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
David Moskowitz, VP Capital Markets Strategy & Investor
Relations (Investor enquiries)
Victoria Stewart, Director of Communications (Media
Enquiries)
N+1 Singer Tel: +44 (0)20 3283 4200
(Nominated Adviser and UK Broker)
Aubrey Powell / George Tzimas / Iqra Amin (Corporate
Finance)
Mia Gardner (Corporate Broking)
Optimum Strategic Communications Tel: +44 (0)20 950 9144
(European Media and Investor Enquiries) verona@optimumcomms.com
Mary Clark / Eva Haas / Hollie Vile
Argot Partners Tel: +1 212-600-1902
(US Investor Enquiries) verona@argotpartners.com
Stephanie Marks / Kimberly Minarovich / Michael Barron
(END) Dow Jones Newswires
January 07, 2020 02:00 ET (07:00 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024